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Abstract
Background: A specific subset of psoriasis patients is characterized by subclinical inflammatory changes.
These patients frequently present with arthralgia and have a higher risk to develop psoriatic arthritis (PsA).
We hypothesized that IL-17A inhibition in this subset of patients can intercept the link between skin and
joint disease and resolves pain and inflammatory changes.
Methods: Psoriasis, but no PsA, patients were included in the open prospective exploratory Interception in very early
PsA (IVEPSA) study. Patients had to have nail or scalp involvement or a high psoriasis area severity index (PASI) (> 6) as
well as inflammatory or erosive changes in MRI or CT. Patients received treatment with the anti-interleukin (IL)-17A
antibody secukinumab over 24 weeks. Clinical assessments of skin and joint disease were done at baseline and after 12
and 24weeks, MRI and CT at baseline and after 24 weeks.
Results: Twenty patients were included, 85% of them reporting arthralgia and 40% had tender joints at the examination.
Eighty-three percent had at least one inflammatory lesion in the MRI, most of them synovitis/enthesitis. Skin disease (PASI:
p< 0.002; BSA: p< 0.003) and arthralgia (VAS pain: p< 0.003) significantly improved after 24weeks. Total PsAMRIS (p= 0.005)
and synovitis subscore (p= 0.008) also significantly improved. Erosions and enthesiophytes did not progress, while bone
mass in the distal radius significantly (p= 0.020) increased after 24 weeks.
Conclusions: These data suggest that very early disease interception in PsA is possible leading to a comprehensive
decline in skin symptoms, pain, and subclinical inflammation. IVEPSA therefore provides rationale for future early
interventions with the concept to prevent the onset of PsA in high-risk individuals.
Trial registration: Trial registry name PSARTROS; trial registry number: NCT02483234; June 26, 2015.
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Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory disease
affecting the joints and entheses, leading to tissue damage
[1]. In the joints, the inflammatory process in PsA afflicts
the synovium and the periosteal insertions of tendons and
ligaments, leading to erosions and enthesiophytes,
respectively [2]. The overwhelming knowledge of PsA
comes from studies in established disease studying pa-
tients with several years of disease duration. Current
knowledge on early disease however is still scarce. None-
theless, a limited number of studies suggest that early PsA
is different from established disease showing only moder-
ate joint swelling but substantial pain and prevalence of
enthesitis [3–6]. Furthermore, early treatment or even
prevention of PsA may result in better outcomes for the
patients [7, 8]. Understanding the biology of early disease
in PsA is of utmost importance, as it will allow earlier
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interference with the disease process and better preven-
tion of damage and disability [9]. This concept becomes
even more important if considering that currently avail-
able intervention strategies for psoriatic disease have vary-
ing effects on the skin and the joints [10].
It seems that the onset of PsA is preceded by a prodromal
phase (“transition phase”), in which the disease starts to
spread from the skin to the joints [11]. This state, which is
characterized by pain and joint tenderness—but no swell-
ing—as well as the presence of distinct inflammatory joint
lesions in the imaging analysis, is associated with a high risk
to develop PsA [12, 13]. Based on these findings, this pro-
dromal phase of the disease would allow developing strat-
egies for early disease interception with the ultimate goal to
prevent the onset of PsA. Before such strategies can be de-
veloped, however, it has to be clarified whether the symp-
toms and subclinical inflammatory joint lesions are
sensitive to therapeutic intervention in principle.
The mechanisms of spreading of inflammatory skin
disease to the joints are currently unknown. Nonethe-
less, some evidence suggests that interleukin (IL)-17A
plays a role in this process: (i) Thus, overexpression of
IL-17 in the skin does not only lead to psoriasis but also
precipitate bone marrow activation and neutrophil re-
cruitment [14]; (ii) IL-17 producing cells have been
shown in the circulation of PsA patients and their num-
ber is associated to disease activity in the joints [15]; and
(iii) IL-17 inhibition has shown to provide comprehen-
sive effects on skin, entheseal, and joint manifestations
of the disease [16, 17]. In addition to these observations,
IL-17 has key effector functions in the joints such as
osteoclast differentiation and bone erosions as well as
most likely initiating altered stress responses in the
joints leading to enthesiophyte formation [18, 19]. These
structural effects of IL-17 have not only been substanti-
ated in radiographic outcomes from the large random-
ized controlled clinical trials [20, 21] but also by smaller
but more in-depth studies [22, 23] that showed an arrest
of both catabolic and anabolic bone changes upon IL-17
inhibition.
Based on these data, we aimed to collect evidence for
the principled possibility of early disease interception in
the prodromal phase of PsA, by exposing psoriasis pa-
tients with active skin disease and subclinical joint in-
flammation in the MRI to anti-IL-17 antibody treatment
with secukinumab for a total period of 24 weeks. We hy-
pothesized that IL-17 inhibition resolves musculoskeletal
pain and the early inflammatory changes in the joints of
psoriasis patients.
Patients and methods
Study design and patients
The IVEPSA study (Interception in very early PsA) is a
single-arm prospective exploratory open-label study to
assess the effects of secukinumab treatment on the in-
flammatory and structural changes in the peripheral
joints of psoriasis (and not PsA) patients. The protocol
has been submitted as part of the PSARTROS study pro-
gram (NCT02483234; June 2015) receiving ethics
approval from the institutional review board (IRB) and
the regulatory authorities. All patients provided written
informed consent. Eligible patients had to have either
moderate to severe psoriasis (PASI score > 6) or scalp or
nail involvement. They also had to have inflammatory or
erosive changes in MRI or erosive changes in the high-
resolution peripheral quantitative computed tomography
(HR-pQCT), but no clinical signs of arthritis at baseline.
Hence, the included patients also did not fulfill the CAS-
PAR criteria of PsA. Patients receiving treatment with
systemic glucocorticoids or conventional or biological
disease-modifying anti-rheumatic drugs (DMARDs)
were not allowed into IVEPSA. Previous use of conven-
tional DMARDs for the treatment of psoriasis was
allowed, while previous use of biological DMARDs was
not allowed. Also, other conditions such as recent live
vaccines, history of tuberculosis, pregnancy, use of opi-
oid analgesics, or drug abuse during the last 6 months
or any uncontrolled medical condition were not allowed.
If eligible, patients started to receive subcutaneous treat-
ment with 300 mg secukinumab once weekly for the first
months and once monthly thereafter for a total period
of 24 weeks.
Table 1 Demographics and baseline clinical characteristics
Demographics
Sex (male, %) 70%
Age (median, IQR) 49.5 (42.8, 59)
Disease duration (median, IQR) 14 (5, 20)
Clinical characteristics
PASI (median, IQR) 6.8 (3.5, 18.6)
BSA% (median, IQR) 10.9 (3.6, 20.3)
Arthralgia (%) 85%
VAS_pain (median, IQR) 18.5 (11.75, 49.5)
VAS_patient global disease activity (median,
IQR)
68 (45, 74)
VAS_physician (median, IQR) 35.5 (8.75, 62.75)
Tender joints (%) 40%
TJC78 (median, IQR; mean ± SD) 0 (0, 3.75); 2.65 ±
5.11
Nail involvement (%) 55%
Scalp involvement (%) 75%
Data are based on all 20 psoriasis patients
IQR interquartile range, SD standard deviation, PASI psoriasis area severity
index, BSA body surface area, VAS visual analogue scale, TJC tender joint count
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Clinical assessments
Demographic parameters such as age, sex, and body
mass index were recorded at baseline. The extent of
skin disease was assessed by the psoriasis area sever-
ity index (PASI) and body surface area (BSA). All
patients were asked for the presence/absence of arth-
ralgia and joint tenderness as well as the severity of
pain (visual analogue scale). In addition, patients’ and
physicians’ ratings of global disease activity were re-
corded. Clinical examination was done for tender
joint count (TJC) 78, swollen joint count 76, and
SPARCC entheseal sites. In addition, the presence/ab-
sence of dactylitis and nail involvement was recorded.
Per definition, patients were not allowed to have joint
swelling, clinical signs of enthesitis, or presence of
dactylitis at baseline. With respect to the impact of
skin and musculoskeletal symptoms on patients’ qual-
ity of life, the dermatology quality of life index
(DLQI) and the psoriatic arthritis impact of disease
(PSAID) questionnaire, respectively, were used.
Magnetic resonance imaging
MRI was used to assess inflammatory and structural
changes in the joints. MRI scans of the dominant hand
were performed at baseline and after 24 weeks of secuki-
numab treatment using a 1.5-T Magneton Avanto sys-
tem (Siemens, Erlangen, Germany) as described before
[22]. T1-weighted images with and without contrast
agent as well as T2-weighted coronal fat saturated
(TIRM) sequences were assessed for synovitis, peri-
articular inflammation, tenosynovitis, and bone erosions,
bone proliferations, and osteitis. Images were evaluated
by two independent assessors (IO, CL) blinded for the
identity of the patients and the sequence of the images
using standardized PsAMRIS-OMERACT scoring [24].
High-resolution peripheral quantitative computed
tomography
HR-pQCT was used to assess the structural changes in
the joints (MCP and PIP) and volumetric bone mineral
density (vBMD) and biomechanical parameters in the
Fig. 1 a–c Effects of secukinumab on signs of MRI inflammation in psoriasis patients at risk to develop PsA. T2-weighted coronal fat saturated
(TIRM) sequences of the hands of psoriasis patients at risk to develop PsA. Three examples, one from metacarpophalangeal joints and two from
the wrist joint, are shown. Left column: overview at baseline; middle column: close-up of the inflammatory lesion at baseline; right column:
follow-up of the same region after 24 weeks of secukinumab treatment. Black arrows mark the lesion; white frames mark the area depicted in
the close-up
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distal radius. HR-pQCT of the dominant hand was per-
formed at baseline and after 24 weeks of secukinumab
treatment using an XtremeCT I scanner (Scanco Med-
ical). Scans were performed at the metacarpophalangeal
(MCP) joints 2–4, the proximal interphalangeal (PIP)
joints 2 and 3, and the distal radius. MCPs and PIPs
were evaluated for erosions (numbers, volume) and
enthesiophytes (grade 1: maximum height ≤ 4 mm; grade
2: maximum height > 4 mm; grade 3: diffuse osteoproli-
feration) as described previously [22]. Bone mass was
assessed in the distal radius including the measurement
of total, trabecular, and cortical vBMD (mg hydroxyapa-
tite (HA) per cm3) as previously described [25]. For
μFEA, finite element analysis software (FAIM, Version
8.0, Numerics88 solution, Calgary, Canada) was used. In
order to generate micro-finite element models, the
segmented trabecular network and cortex of the HR-
pQCT images were used [26, 27]. Mesh size of the
resulting models ranged from 1.5 to 3.5 million equally
sized brick elements. Single linear isotropic tissue mod-
eling was applied by assigning a tissue modulus of 6829
MPa and a Poisson’s ratio of 0.3 homogeneously to each
element [28]. A linear uniaxial compression test was
simulated. Nodes on the proximal bone surface were
fixed in the z direction but unconstrained in x and y di-
rections. Nodes on the distal bone surface were also free
in x and y directions but exposed to a displacement
equivalent to 1% strain along the z-axis [28]. Axial bone
stiffness (kN/mm) as reaction force (RFz) divided by
average displacement of the distal surface (Uz) and bone
strength as estimated failure load (N) based on the
Pistoia criterion was calculated [29].
Statistical analysis
The hypothesis of the study was that secukinumab treat-
ment leads to a significant improvement of (i) MRI syno-
vitis and periarticular inflammation and (ii) pain and joint
tenderness after 24 weeks. Wilcoxon signed-rank test was
used for paired comparisons between baseline and week
24. Cross-sectional analyses were performed using the
Mann-Whitney U test for differences and the Spearman
correlation for relations. Due to the exploratory nature of
the study, no sample size calculation was made. Statistical
significance was set at p ≤ 0.05, data presented as median
and quartiles. All analyses were performed in a two-tailed
manner using IBM SPSS version 21.
Results
Baseline characteristics of the psoriasis patients
Twenty psoriasis patients were prospectively included in
the study; 70% of them were males. Median age was
49.5 years (IQR 42.8, 59) and median disease duration
14 years (IQR 5, 20). Patients had moderate-to-high
psoriasis activity at baseline according to PASI (median
6.9; IQR 3.5, 18.6) and BSA (median 10.9%; IQR 3.6%,
20.3%). Nail involvement was present in 55% and scalp
involvement in 75% of the patients. Reported arthralgia
was common at baseline and occurred in 85% (17/20) of
patients. It was mostly based on inflammatory arthralgia
(15/17); however, intensity was low with median VAS
pain score of 18.5 (IQR 11.7, 49.5). The majority of pa-
tients with arthralgia (80%) reported an affection of the
dominant hand, on which imaging was performed. Forty
percent of patients had tender joints at examination
(median TJC78 0, IQR 0, 3.8), but no patient had joint
swelling. Patient demographics and clinical characteris-
tics are summarized in Table 1. No patient had concomi-
tant conventional DMARD or systemic steroid
treatment during the study. Twenty-five percent of the
patients had received previous treatment with
Table 2 Baseline imaging characteristics
MRI
Synovitis (%) 66.7%
PSAMRIS synovitis (median, IQR) 1 (0, 2)
PSAMRIS synovitis (mean ± SD) 2.17 ± 4.6
Osteitis (%) 27.8%
PSAMRIS osteitis (median, IQR) 0 (0, 0)
PSAMRIS osteitis (mean ± SD) 0.44 ± 1.89
Erosion (%) 72.2%
PSAMRIS erosion (median, IQR) 1 (0, 4)
PSAMRIS erosion (mean ± SD) 2.56 ± 3.7
Proliferation (%) 33.3%
PSAMRIS proliferation (median, IQR) 0 (0, 1)
PSAMRIS proliferation (mean ± SD) 0.44 ± 0.71
Periarticular (%) 16.7%
PSAMRIS periarticular (median, IQR) 0 (0, 0)
PSAMRIS periarticular (mean ± SD) 0.28 ± 0.67
Tenosynovitis (%) 55.6%
PSAMRIS tenosynovitis (median, IQR) 0 (0, 1)
PSAMRIS tenosynovitis (mean ± SD) 0.61 ± 1.15
Total PSAMRIS (median, IQR) 4 (0.75, 7.25)
Total PSAMRIS (mean ± SD) 6.5 ± 8.85
HR-pQCT
Erosions (%) 58.8%
Erosion no. (median, IQR) 1 (0, 1.75)
Enthesiophytes (%) 41.2%
Grade 1 23.5%
Grade 2 17.6%
Grade 3 0%
Data are based on 18 psoriasis patients who completed the study
PSAMRIS psoriatic arthritis magnetic resonance imaging scoring system, MRI
magnetic resonance imaging, HR-pQCT high-resolution peripheral quantitative
computed tomography, IQR interquartile range, SD standard deviation
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methotrexate, and 20% were previously treated with di-
methyl fumarate. One patient discontinued the treat-
ment due to lack of efficacy at week 12, and another
patient could not perform the follow-up MRI.
Baseline imaging features of the psoriasis patients
Baseline MRI investigation revealed at least one inflam-
matory lesion in 83.3% of patients (for examples, see Fig.
1). Synovitis was the most prevalent (66.7%), followed by
tendinitis (55.6%), osteitis (27.8%), and periarticular in-
flammation (16.7%). Median total PsAMRIS score was
2.5 (IQR 0, 6). Erosions were present in 72.2% and 56.3%
in the MRI and HR-pQCT, respectively, and enthesio-
phytes were found in 33.3% and 37.5%, respectively.
More specifically, all enthesiophytes demonstrated in
HR-pQCT were graded either as mild (grade 1, 23.5%)
or as moderate (grade 2, 17.6%). No cases of severe dif-
fuse osteoproliferation were recorded. All baseline im-
aging data are presented in Table 2.
Effects of secukinumab treatment on psoriatic skin
disease and musculoskeletal symptoms
Psoriatic skin disease (total PASI and BSA) significantly
improved after 24 weeks of secukinumab treatment
(Table 3; Fig. 2a): PASI significantly (p = 0.002) declined
from a median score of 6.9 at baseline to 0.4 after 24
weeks. BSA also significantly (p = 0.003) decreased
from a median of 10.9% at baseline to 0.2% at follow-
up. In accordance, skin disease-related quality of life
of the patients measured by improved DLQI signifi-
cantly (p = 0.0009) improved. Extent of arthralgia sig-
nificantly (p = 0.003) declined after secukinumab
treatment from a median of 18.5 mm at baseline to a
median of 7 mm at follow-up (Table 3; Fig. 2b). In ac-
cordance, we observed a significant improvement of
patients global (p = 0.003) as well as a significantly
(p = 0.0014) lower impact of musculoskeletal
symptoms on patients’ quality of life as measured by
the PSAID. In patients with MRI inflammation at
baseline, also the number of painful joints at baseline
(1, IQR 0, 4) significantly improved at week 24 (0,
IQR 0, 2; p = 0.038) (Table 3). No patient developed
PsA during the observation period.
Effects of secukinumab treatment on subclinical
inflammation and local bone changes
Sequential assessment of joint inflammation by MRI showed
a significant decrease in global PsAMRIS (p= 0.005) and
PsAMRIS synovitis score (p= 0.008) after 24weeks of secuki-
numab treatment (Table 4). Furthermore, periarticular
Table 3 Changes in signs and symptoms of psoriasis between baseline and week 24
Baseline Week 24 p value
Characteristic (n = 18)
PASI (median, IQR) 6.9 (3.5, 18.6) 0.4 (0, 1.5) 0.002**
BSA% (median, IQR) 10.9 (3.6, 20.3) 0.2 (0, 1.8) 0.003**
DLQI (median, IQR) 10 (5, 15) 1.5 (0.75, 5.75) 0.003**
VAS pain (median, IQR) 18.5 (11.75, 49.5) 7 (1, 14) 0.003**
VAS global (median, IQR) 68 (45, 74) 8 (2.5, 26) < 0.001**
VAS physician (median, IQR) 35.5 (8.75, 62.75) 7 (1, 15) 0.011*
TJC 78 (median, IQR) (mean ± SD)† 0 (0, 3.75); 2.65 ± 5.11 0 (0, 2); 0.63 ± 1.17 0.102
PsAID (median, IQR) 3.5 (1.65, 1.7) 1.35 (0.2, 2.35) 0.003**
Characteristic (n = 15)
PASI (median, IQR) 6.9 (3.3, 15.4) 0.3 (0, 1.1) 0.007**
BSA% (median, IQR) 9.2 (4.3, 18.1) 0.05 (0, 1) 0.013*
DLQI (median, IQR) 12 (6.75, 15.75) 2 (0.75, 8.25) 0.013*
VAS pain (median, IQR) 26 (14, 50) 4 (1, 23) 0.004**
VAS global (median, IQR) 70 (61, 75) 12 (1, 38) 0.001**
VAS physician (median, IQR) 37 (7, 50) 4 (1, 22) 0.036*
TJC 78 (median, IQR) (mean ± SD)† 1 (0, 4); 3.53 ± 5.67 0 (0, 2); 0.53 ± 0.92 0.038*
PsAID (median, IQR) 3.7 (2.84, 6.01) 1.45 (0.25, 3.2) 0.005**
Data on the upper half are based on 18 psoriasis patients with complete baseline and 24-week data. Data on the lower half are based on patients with active
joint inflammation in MRI at baseline (n = 15)
TJC tender joint count, VAS visual analogue scale, PASI psoriasis area and severity index, BSA% percent body surface area, IQR interquartile range, DLQI
dermatology life quality index, PsAID psoriatic arthritis impact of disease
†Additionally reported as mean and standard deviation (mean ± SD) because median was equal to zero
Wilcoxon signed-rank test. *p ≤ 0.05, **p ≤ 0.01
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inflammation completely disappeared. Importantly, improve-
ment in total PsAMRIS score significantly correlated with
the improvement in arthralgia (VAS pain score difference,
p= 0.009) but not with skin disease (Fig. 2c, d).
We also examined whether secukinumab therapy ar-
rests the progression of structural damage in psoriasis
patients. Bone erosions were assessed at baseline and
after 24 weeks of secukinumab treatment using MRI and
HR-pQCT. In MRI and in HR-pQCT, PsAMRIS erosion
score and numbers respectively remained stable over the
24 weeks of treatment with no signs of progression
(Table 4). Interestingly, patients with erosions presented
with higher level of arthralgia at baseline and after secu-
kinumab treatment (week 24) (p = 0.044 and 0.025,
respectively). We also checked the progression of enthe-
siophytes, which are a hallmark of structural damage in
psoriasis. In the MRI, where osteoproliferation is also
scored, no progression was found. In the HR-pQCT,
which is more sensitive for enthesiophytes, no progres-
sion of proliferation numbers or grade was detected dur-
ing the treatment with IL-17 inhibitor. Overall, no
progression of catabolic and anabolic bone changes was
found during the treatment in this prodromal phase of
PsA.
Effects of IL-17 blockade on bone structure and
biomechanical properties
We finally investigated bone volumetric density (vDMD)
and biomechanical properties at the distal radius. Small
but significant increase of vBMD was observed from
baseline (303.1 HA/cm3) to follow-up (308.9 HA/cm3;
p = 0.020) (Table 4). Also, trabecular vBMD significantly
improved from baseline (165.2 HA/cm3) to follow-up
(165.7 HA/cm3; p = 0.048). Cortical vBMD remained
stable, and also, biomechanical bone parameters such as
failure load and stiffness resembling biomechanical
properties of the bone remained stable (Table 4).
Discussion
Transition from psoriatic skin disease to PsA is an import-
ant step as PsA is associated with substantially higher dis-
ease burden due to pain and functional impairment.
Furthermore, structural changes accrue in PsA, represent-
ing an irreversible damage to tissue architecture in the
Fig. 2 Effects of secukinumab on skin and musculoskeletal manifestations of psoriasis patients at risk to develop PsA. a Baseline and 24-week
psoriasis area severity index (PASI), body surface area (BSA), and dermatology quality of life index (DLQI) in psoriasis patients at risk to develop
PsA. b Baseline and 24-week visual analogue scale (VAS) for pain, VAS for global musculoskeletal disease activity, and psoriatic arthritis impact of
disease (PSAID) in psoriasis patients at risk to develop PsA. c Correlation between total psoriatic arthritis magnetic resonance imaging score
(PsAMRIS) and PASI score. d Correlation between total PsAMRIS and VAS for pain
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joints and in the entheses. It is well known that psoriasis
typically precedes the development of PsA, allowing defin-
ing a population at-risk for developing PsA. However, if
looking at an unselected group of psoriasis patients, the
progression rate to PsA is rather limited, necessitating the
definition of specific subpopulations of psoriasis patients
that show a high risk to develop joint disease [30]. Such
populations may profit best from the early systemic treat-
ment of the disease [10].
IVEPSA shows the principled feasibility to identify a
subset of psoriasis patients, who show symptoms as well
as subclinical signs of inflammation suggestive for the
prodromal phase of PsA, and the possibility to treat such
patients with systemic cytokine neutralization leading to
regression of inflammatory lesions and improvement of
joint pain. Psoriasis patients in this study had to have
previously defined risk factors such as nail or scalp
involvement or moderate to severe psoriasis [31]. How-
ever, the mere fulfillment of such risk factors may not be
enough to sufficiently pin down the population with
high risk for PsA. Therefore, we have built on previous
data that showed that subclinical inflammatory lesions
in the joints of psoriasis patients massively enhance the
risk for the development of PsA, resembling a popula-
tion that closely resembles the prodromal phase of PsA
[7]. This subgroup of psoriasis patients is also character-
ized by a high prevalence of joint pain, showing parallels
to observations made in RA, where pain and subclinical
inflammatory lesions precede the onset of joint disease.
Notably, none of our patients had signs of PsA such as
joint swelling, clinical enthesitis, or dactylitis.
Inhibition of IL-1A by secukinumab not only signifi-
cantly improved psoriatic skin lesions but also reduced
pain and subclinical inflammatory lesions in psoriasis
patients in the prodromal phase of PsA. This effect was
accompanied by an improvement of quality of life with
respect to skin and musculoskeletal manifestations of
the disease. This observation suggests that joint pain as
well as the development of the articular MR lesions
depends on IL-17 activity. We think that this is an
important finding as it indicates that symptoms and MR
lesions in this prodromal phase of the disease are not
unspecific in their nature but related to the disease
process. This notion is in line with the observation of a
significant relation between pain responses and the re-
duction of MR lesions.
Our data give support to the concept that selective in-
terventions in a defined subset of psoriasis patients may
be a feasible approach to prevent the onset of PsA. The
concept to prevent PsA by interfering early in the
process of psoriatic disease is appealing but challenging
as the success of such studies depends on the appropri-
ate intervention and the right selection of patients. An
unselected approach in all-comers with psoriasis seems
hardly feasible based on the large number of patients to
be included and the long duration of such study.
Table 4 Changes of the inflammatory and structural parameters between baseline and week 24
Characteristic Baseline Week 24 p value
MRI
PSAMRIS synovitis (median, IQR) (mean ± SD)† 1 (0, 2); 2.17 ± 4.61 1 (0, 2); 1.06 ± 1.96 0.008**
PSAMRIS osteitis (median, IQR) (mean ± SD)† 0 (0, 0); 0.44 ± 1.89 0 (0, 0); 0.33 ± 1.41 0.317
PSAMRIS periarticular (median, IQR) (mean ± SD)† 0 (0, 0); 0.28 ± 0.67 0 (0, 0); 0 ± 0 0.102
PSAMRIS tenossynovitis (median, IQR) (mean ± SD)† 0 (0, 1); 0.61 ± 1.15 0 (0, 0); 0.33 ± 0.84 0.096
PSAMRIS erosions (median, IQR) 2 (0, 4) 2 (0, 4) 1.000
PSAMRIS proliferation (median, IQR) (mean ± SD)† 0 (0, 1); 0.44 ± 0.71 0 (0, 1); 0.44 ± 0.86 1.000
Total PSAMRIS (median, IQR) 5 (1, 8) 3 (0, 6) 0.005**
HR-pQCT
Erosion number (median, IQR) 1 (0, 1.75) 1 (0, 1.75) 0.317
Proliferation grade (median, IQR) (mean ± SD)† 0 (0, 1); 0.55 ± 0.76 0 (0, 2); 0.68 ± 0.89 0.180
Dtot, HA/cm3 (median, IQR) 303.1 (264.8, 320.8) 308.9 (265.8, 324.9) 0.020*
Dtrab, HA/cm3 (median, IQR) 165.2 (133.5, 205.7) 165.7 (136.9, 206.9) 0.048*
Dcomp, HA/cm3 (median, IQR) 840.5 (778.8, 848.3) 831.1 (796.5, 854.8) 0.184
Bone stiffness, kN/mm (median, IQR) 48.38 (38.58, 60.31) 49.40 (38.14, 59.82) 0.501
Failure load, N (median, IQR) 2312.2 (1862.6, 2817.0) 2390.0 (1798.6, 2847.2) 0.352
Data are based on 18 psoriasis patients with complete baseline and 24-week data
PSAMRIS psoriatic arthritis magnetic resonance imaging scoring system, MRI magnetic resonance imaging, HR-pQCT high-resolution peripheral quantitative
computed tomography, IQR interquartile range, Dtot average bone density, HA hydroxyapatite, Dtrab trabecular bone density, Dcomp cortical bone density,
N Newton
†Additionally reported as mean and standard deviation (mean ± SD) because median was equal to zero
Wilcoxon signed-rank test. *p ≤ 0.05, **p ≤ 0.01
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Therefore, rigorous selection of psoriasis patients that
are in transition to PsA seems necessary, and this ex-
ploratory study provides the basis for such approach
[10]. The limitation of this study is the small number of
patients and the observational character without inclu-
sion of placebo control. Therefore, results have to be
interpreted with caution. Notably, this study has not
been designed to answer the question if PsA can be pre-
vented but rather tested the feasibility to identify a
population of imminent PsA, treat such population with
cytokine inhibitors, and show a biological effect on sub-
jective and objective signs of inflammation. Based on
these findings, larger randomized controlled studies can
be designed.
Early intervention is yet an under-recognized clinical
unmet need in PsA. Thus, virtually, all interventional
studies to date have focused on established disease, in
which substantial joint damage has already accrued.
IVEPSA data show that even in this very early popula-
tion, some catabolic and anabolic bone damage can be
observed, suggesting the need for early intervention. The
observation of a higher prevalence of erosions than
enthesiophytes in this population was at first sight sur-
prising, as previous studies revealed enthesiophytes as
first musculoskeletal lesions in psoriasis [23, 32, 33],
however, but may be owed to the fact that in this case a
population with subclinical inflammatory lesions in the
joints has been selectively studied. Furthermore, the data
also show that inhibition of IL-17 arrests the progression
of catabolic and anabolic changes in the joints of these
patients. This finding is in accordance with the one ob-
tained in established disease using high-end imaging, but
the difference is that in the IVEPSA population, bone
damage is halted at a much less progressed stage.
Although the study design does not allow to judge
whether structural progression would have occurred in
the absence of treatment, previous data showed that
HR-pQCT allows detecting structural progression within
the same time frame in PsA patients treated with metho-
trexate or TNF inhibitors [34].
Conclusions
Feasibility of disease interception in very early psoriatic
arthritis
Taken together, the data obtained in the IVEPSA study
suggest that early therapeutic intervention during the
transition phase from psoriasis to PsA is feasible and as-
sociated with improvement in the clinical and imaging
manifestations of emerging PsA. Thereby, this study pro-
vides the rationale for early disease interception with the
vision to prevent PsA.
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